A Phase II Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer (47-02-001).
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs PG 11047 (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 18 Apr 2009 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 06 Nov 2006 New trial record.